Clinical trials: psoriasis
Spondylitis, Ankylosing, Arthritis, Psoriatic
A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis
The purpose of this study is to assess the safety of subcutaneous (SC) golimumab in participants with active Ankylosing Spondylitis (AS) or Psoriatic Arthritis (PsA) over 24 weeks.
- Trial name
- NCT03733925
- Testing
- Golimumab
- Where
- 9 sites in India
- Volunteers
- 100 people
- Sponsor
- Johnson & Johnson Private Limited
Psoriasis
Five-Year Observation of Remicade Treatment for Plaque Psoriasis in Austria (Study P04900)
Prospective, open-label-, 1-arm, multicenter observational study to determine the dose and interval of Infliximab infusions for subjects with plaque psoriasis.
- Trial name
- NCT00725452
- Testing
- Infliximab
- Volunteers
- 26 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriatic Arthritis
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis, specifically in improving signs and symptoms of psoriatic arthritis (tender and swollen…
- Trial name
- PALACE-1 (NCT01172938)
- Testing
- Apremilast 20mg, Apremilast 30mg
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 504 people
- Sponsor
- Amgen
Psoriasis
Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis
This study is an open-label extension of study 20090062 to evaluate extended subcutaneous dosing.
- Trial name
- NCT01101100
- Testing
- AMG 827
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 181 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis, Cardiovascular Disease
Vascular Inflammation in Psoriasis Trial (The VIP Trial)
The purpose of this study is to assess the effect of adalimumab (Humira), when compared to NB-UVB (narrow-band ultraviolet B) phototherapy or placebo (an inactive substance that may resemble an active substance but has no medical…
- Trial name
- VIP (NCT01553058)
- Testing
- Adalimumab (Humira), NB-UVB phototherapy
- Where
- 9 sites in United States
- Volunteers
- 97 people
- Sponsor
- University of Pennsylvania
Plaque Psoriasis, Psoriasis
Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis
The purpose of this study is to compare the safety and efficacy of different doses of etanercept for the treatment of moderate to severe psoriasis.
- Trial name
- PRISTINE (NCT00663052)
- Testing
- Etanercept
- Where
- 38 sites in Argentina, Austria and 11 more
- Volunteers
- 273 people
- Sponsor
- Pfizer
Plaque Psoriasis
Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis
The objective of the study is to evaluate the safety and efficacy of a topical lotion
- Trial name
- NCT02045277
- Testing
- IDP-118 Lotion, IDP-118 Monad HP Lotion, IDP-118 Monad Taz Lotion
- Where
- 18 sites in United States
- Volunteers
- 212 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriatic Arthritis
A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis
The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drugs (DMARD) naive.
- Trial name
- SPIRIT-H2H (NCT03151551)
- Testing
- Ixekizumab, Adalimumab
- Where
- 131 sites in Argentina, Australia and 20 more
- Volunteers
- 566 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/or palms of the hands and the soles of the feet).
- Trial name
- ICONIC-TOTAL (NCT06095102)
- Testing
- JNJ-77242113
- Where
- 90 sites in United States, Argentina and 9 more
- Volunteers
- 311 people
- Sponsor
- Janssen Research & Development, LLC
Psoriatic Arthritis
AMG 827 in Subjects With Psoriatic Arthritis
The study will examine the safety and effectiveness of AMG 827 for the treatment of psoriatic arthritis
- Trial name
- NCT01516957
- Testing
- AMG 827 140, AMG 827 280, AMG 827 210
- Where
- 31 sites in United States, Canada
- Volunteers
- 168 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis Vulgaris
LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris
The purpose is to compare the efficacy of treatment with LEO 90100 at Week 4 to that of calcipotriol plus betamethasone dipropionate (BDP) gel at Week 8 in subjects with psoriasis vulgaris
- Trial name
- NCT02132936
- Testing
- LEO 90100 aerosol foam, Aerosol foam vehicle, Calcipotriol BDP gel
- Where
- France
- Volunteers
- 504 people
- Sponsor
- LEO Pharma
Nail Psoriasis, Plaque Psoriasis
Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis
The purpose of this study is to evaluate if Etanercept administered at a higher initial dose provides greater improvement in nail and skin psoriasis symptoms than a regimen with a lower initial dose.
- Trial name
- NCT00581100
- Testing
- etanercept
- Volunteers
- 136 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Psoriasis
Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis
The study evaluated the efficacy of AMG 827 compared with placebo as measured by the percent of improvement in PASI score at week 12.
- Trial name
- NCT00975637
- Testing
- 70 mg SC, 210 mg SC, 140 mg SC
- Volunteers
- 198 people
- Sponsor
- Bausch Health Americas, Inc.
Plaque Psoriasis
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Plaque Psoriasis
- Trial name
- NCT02932878
- Testing
- DSXS topical
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
This was a multinational, multicenter, randomized, double-blind, placebo controlled study with randomized withdrawal and retreatment, evaluating the safety and efficacy of risankizumab 150 mg subcutaneous (SC) in participants…
- Trial name
- NCT02672852
- Testing
- Risankizumab
- Volunteers
- 507 people
- Sponsor
- AbbVie
Plaque Psoriasis
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.
- Trial name
- IXORA-P (NCT02513550)
- Testing
- Ixekizumab
- Where
- 125 sites in United States, Argentina and 12 more
- Volunteers
- 1,257 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis
A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)
This Phase 3 study has been designed to determine and compare the efficacy and safety of 000-0551 Lotion and Vehicle Lotion applied twice daily for two weeks in subjects with plaque psoriasis.
- Trial name
- NCT01882647
- Testing
- 000-0551 Lotion, Vehicle Lotion
- Where
- 11 sites in United States
- Volunteers
- 222 people
- Sponsor
- Therapeutics, Inc.
Psoriasis Vulgaris
A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis
The primary objective is to demonstrate added benefit of brodalumab versus a selected systemic comparator in treatment of moderate to severe plaque psoriasis in Germany in subjects who have not previously received systemic…
- Trial name
- NCT03331835
- Testing
- Brodalumab, Fumaric acid esters
- Where
- 30 sites in Germany
- Volunteers
- 210 people
- Sponsor
- LEO Pharma
Rheumatoid Arthritis, Psoriatic Arthritis
Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)
Rheumatoid arthritis (RA) is an inflammatory form of arthritis that causes joint pain and damage. RA attacks the lining of the joints (synovium), causing swelling that can result in aching and throbbing, and eventually deformity.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Periodontal Disease
- Trial name
- NCT01198509
- Testing
- doxycycline, vancomycin
- Where
- 2 sites in United States
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Psoriatic Arthritis
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
This study was to provide 24 - 52 week efficacy, safety and tolerability data to support the registration of the secukinumab (AIN457) prefilled syringe (PFS) for subcutaneous self administration in subjects with active PsA…
- Trial name
- FUTURE 2 (NCT01752634)
- Testing
- Secukinumab (AIN457)
- Where
- 76 sites in United States, Australia and 9 more
- Volunteers
- 397 people
- Sponsor
- Novartis Pharmaceuticals